ResMed Inc.

RMD Healthcare Medical Instruments & Supplies

ResMed Inc.’s revenue for fiscal 2026 (year ended June 2026) was $5.7 billion, up 9.85% from fiscal 2025. In the quarter to June 2026, revenue grew 8.58%, EPS grew 2.32%, free cash flow fell 21.3% and total debt fell 39.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten, operating cash flow growth for three.

238.97 3.26 −1.35%
Market cap
$34.1B
P/E
22.8×
Fwd P/E
16.6×
Dividend yield
1.03%
F-score
6/9
Altman Z
10.00
Beneish M
−2.59
Dividend safety
96/100

ResMed Inc. (RMD) Operating cash flow

Alert me on Operating cash flow

ResMed Inc.'s operating cash flow for fiscal 2026 was $1.8B, unchanged from fiscal 2025. Over the past ten years it has ranged from $351.1M (fiscal 2022) to $1.8B (fiscal 2026) — the current reading is the highest in ten years. Operating cash flow has risen for 4 consecutive fiscal years. ResMed Inc. ranks 5th of 54 Medical Instruments & Supplies companies by operating cash flow.

Operating cash flow, annual

Embed this chart

Annual newest first

Period Operating cash flow Change
FY2026 $1.8B 3.10%
FY2025 $1.8B 25.00%
FY2024 $1.4B 102.11%
FY2023 $693.3M 97.44%
FY2022 $351.1M (52.34%)
FY2021 $736.7M (8.17%)
FY2020 $802.3M 74.76%
FY2019 $459.1M (9.10%)
FY2018 $505.0M 21.97%
FY2017 $414.1M (24.43%)

Quarterly newest first

Period Operating cash flow Change
Jun 2026 $454.6M (17.96%)
Mar 2026 $554.1M 63.10%
Dec 2025 $339.7M (25.71%)
Sep 2025 $457.3M (15.12%)
42 more quarters

Against its own ten years

Low $351.1M High $1.8B
Ten-year median $620.6M
Current reading's percentile 100

Operating cash flow against peers

What Operating cash flow is

Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.

Reported line item

The full definition of Operating cash flow →

More on RMD